Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual Symposium
03/28/2023 - 07:00 AM
CAMBRIDGE, Mass. , March 28, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate in the Cantor Future of Oncology Virtual Symposium, taking place April 3-5, 2023 .
Event: Cantor Future of Oncology Virtual SymposiumPanel Date / Time: Monday, April 3 rd at 2:00pm ET
A live webcast will be available for registered attendees and clients of Cantor.
About Theseus Pharmaceuticals, Inc. Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies. Theseus is working to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) to target all classes of cancer-causing and resistance mutations that lead to clinically relevant variants in a particular protein in a given type of cancer. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing THE-349, a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC), and a pan-variant BCR-ABL inhibitor for the treatment of relapsed/refractory chronic myeloid leukemia (CML) and newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). For more information, visit www.theseusrx.com .
Media Contact Christen Baglaneas Director, Corporate Communications & Investor Relations Theseus Pharmaceuticals 857-706-4993christen.baglaneas@theseusrx.com
Investor Contact Josh Rappaport Stern Investor Relations 212-362-1200josh.rappaport@sternir.com
View original content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-to-participate-in-the-cantor-future-of-oncology-virtual-symposium-301782407.html
SOURCE Theseus Pharmaceuticals
Theseus Pharmaceuticals Inc
THRX Rankings
#4910 Ranked by Stock Gains
THRX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
About THRX
theseus pharmaceuticals is passionately committed to outsmarting cancer resistance. cancer is constantly mutating, allowing it to evade initially effective oncology treatments. theseus believes we can predict how cancer will change, enabling new therapies to stay ahead of future mutations and overcome the demonstrated burden of treatment resistance. led by a team of pioneers in the discovery and development of tyrosine kinase inhibitors (tkis), we are developing best-in-class, pan-variant kinase inhibitors, to shape the future of targeted oncology.